Chisari CG, Comi G, Filippi M, Paolicelli D, et al. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. J Neurol 2021 Jun 28. pii: 10.1007/s00415-021-10676.
PMID: 34181077